Patients with diabetes mellitus routinely have glycohemoglobin (GHb) testing performed to monitor glycemic control and assess risk for developing complications of their disease (1 ). The accuracy of several GHb methods can be adversely affected by the presence of hemoglobin (Hb) C or S trait (2-6 ). It has been estimated that there are at least 200 000 Americans with diabetes mellitus who also have either Hb C or S trait (6 ). We have recently shown that the presence of Hb C or S trait does not affect the accuracy of GHb measurements made by the CLC 330 boronate affinity HPLC method (7 ). We therefore evaluated the effects of Hb C and S traits on 11 commercial GHb methods, using the CLC 330 assay as the comparison method.
heterozygous Hb S) were compared with those obtained by the CLC 330 comparison method. An overall test of coincidence of two least-squares linear regression lines was performed with SAS software (SAS Institute) to determine whether the presence of Hb C or S trait caused a statistically significant difference (P Ͻ0.01) in results relative to the comparison method. Deming regression analysis was performed to determine whether the presence of Hb C or S trait produced a clinically significant effect on GHb results. Given recommendations by the American Diabetes Association of an upper reference limit of 6% and an action limit of 8%, we chose Hb A 1c evaluation limits of 6% and 9%. After correcting for possible calibration bias by comparing results from the homozygous Hb A sample group, we evaluated method bias attributable to the presence of Hb C or S trait, with a clinical significant difference being Ͼ10% (i.e., 0.6% at 6% Hb A 1c and 0.9% at 9% Hb A 1c ).
The presence of Hb C trait produced statistically significant differences (P Ͻ0.01) for all methods tested except for the DiaSTAT, HA8160, and PDQ methods. The presence of Hb S trait produced statistically significant differences for all methods except for the D-10 and PDQ methods. Box-plots for each combination of sample type and method are shown in Fig. 1 . We observed no clinically significant interference attributable to Hb C or S trait with the A1c 2.2 Plus, Dimension RxL, G7, HA 8160, HA 8160 BT, and PDQ methods ( Table 1) . The presence of both Hb C and S traits produced clinically significant positive biases for the A1cNow and VARIANT II methods at 6% and 9% Hb A 1c , respectively. Hb C trait produced a clinically significant negative bias for the D-10 method at 9% Hb A 1c . Hb S trait produced a clinically significant positive bias at 6% Hb A 1c for both the DiaSTAT and DS5 methods. Several methods, including the D-10, DiaSTAT, Dimension RxL, DS5, HA8160, and VARIANT II, showed increased scatter when samples containing Hb C or S trait were tested compared with that seen for samples homozygous for Hb A.
Our results have several similarities to previous studies. For example, one immunoassay method, the Dimension RxL, exhibited no clinically significant effect with either Hb C or S trait, but another immunoassay method, the A1cNow, exhibited a clinically significant positive bias with samples containing both Hb C and S traits. The Unimate and Cobas Integra immunoassay methods have been shown to exhibit a positive bias with both Hb C and S traits, whereas the DCA 2000, Tina-quant, and SYN-CHRON CX 7 methods exhibit no clinically significant bias with either Hb C or S trait (3, 4, 6 ) . Likewise, several ion-exchange methods, including the A1c 2.2 Plus, G7, and HA8160, were not affected by either Hb C or S traits. The DiaSTAT, DS5, and VARIANT II all exhibited a clinically significant positive bias with samples containing Hb S trait. It has previously been shown that some ion-exchange methods, including the Diamat, HA8140, and VARIANT, have a positive bias with samples containing Hb S trait (4, 6 ) . It is noteworthy that two ionexchange methods in the present study exhibited a cliniTechnical Briefs cally significant bias with samples containing Hb C trait. The D-10 method exhibited a negative bias, whereas the VARIANT II exhibited a positive bias. If a method demonstrates a positive bias attributable to Hb variants, then overly rigorous blood glucose control may be instituted with a concomitant increase in hypoglycemic episodes. If a method demonstrates a negative bias, then more rigorous blood glucose control may not be instituted, and the patient may have poorer glycemic control than is optimal.
We have previously examined the effects of Hb C and S traits on the A1c 2.2 Plus and VARIANT II ion-exchange methods (4, 6 ) . Neither method exhibited a clinically significant effect with either variant Hb in these earlier reports. In our present study, the A1c 2.2 Plus method exhibited no clinically significant effects with either variant Hb, but the VARIANT II method exhibited clinically significant effects for both Hb C and S traits. We have previously noted that another ion-exchange GHb method may intermittently show effects with Hb S trait samples, and we speculated that it may be attributable to variabil- Low serum concentrations of vitamin B 12 (cobalamin) have been observed in users of oral contraceptives (OCs) (1 ), in women during pregnancy (2 ) , and in men treated with high doses of ethinylestradiol for prostate cancer (3 ).
Similar effects of hormone replacement therapy (HRT) have been noticed by some (4 ) but not all investigators (5 ).
Serum cobalamin has low diagnostic accuracy as a marker of vitamin B 12 status (6 ) . Because of the long-term consequences of cobalamin deficiency [see Ref. (7 ) for a review], it is important to investigate whether decreased total cobalamin in OC or HRT users is associated with other evidence of impaired cobalamin status, such as increased plasma concentrations of methylmalonic acid (MMA) and total homocysteine (tHcy) and decreased plasma concentrations of holo-transcobalamin (holoTC) (8 ).
We performed a cross-sectional study on 264 female healthcare students and workers. All participants gave written informed consent, and the study was approved by the Regional Ethical Committee and by the Norwegian Social Science Data Services. Study groups were OC users (n ϭ 54) and controls (n ϭ 81; age range, 18 -40 years) and HRT users (n ϭ 51) and controls (n ϭ 78; age range, 41-65 years). Venous blood samples were collected over 6 months on a single occasion from each of the 264 consecutive nonfasting individuals. Blood samples used for tHcy measurements were immediately placed on ice, and EDTAplasma was separated within 2 h after collection. For serum, blood was allowed to clot at room temperature for 30 min before centrifugation. The samples were kept at Ϫ80°C until analysis, and the maximum storage time was 2.5 years.
Serum creatinine was analyzed by the Jaffe alkaline picrate method, and plasma MMA, plasma tHcy (9 ), serum folate, whole-blood cell folate (10, 11 ), serum cobalamin (12 ), and plasma holoTC (13 ) were measured with the cited methods. A more detailed description of the methods is given in the online Data Supplement.
We 
